Compare · EW vs HDSN
EW vs HDSN
Side-by-side comparison of Edwards Lifesciences Corporation (EW) and Hudson Technologies Inc. (HDSN): market cap, price performance, sector, and recent activity on the wire.
Summary
- EW operates in Health Care, while HDSN operates in Consumer Discretionary - the two are in different parts of the market.
- EW is the larger of the two at $49.83B, about 234.0x HDSN ($213.0M).
- Over the past year, EW is up 18.8% and HDSN is down 44.5% - EW leads by 63.3 points.
- EW has been more active in the news (5 items in the past 4 weeks vs 3 for HDSN).
- EW has more recent analyst coverage (25 ratings vs 11 for HDSN).
- Company
- Edwards Lifesciences Corporation
- Hudson Technologies Inc.
- Price
- $86.28-2.03%
- $4.99-1.19%
- Market cap
- $49.83B
- $213.0M
- 1M return
- -2.20%
- -3.11%
- 1Y return
- +18.77%
- -44.55%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 5
- 3
- Recent ratings
- 25
- 11
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Hudson Technologies Inc.
Hudson Technologies, Inc. a refrigerant services company, provides solutions to recurring problems within the refrigeration industry primarily in the United States. The company's products and services include refrigerant and industrial gas sales; refrigerant management services consisting primarily of reclamation of refrigerants, re-usable cylinder refurbishment, and hydrostatic testing services; and RefrigerantSide services comprising system decontamination to remove moisture, oils, and other contaminants. It also offers SmartEnergy OPS service, a web-based real time continuous monitoring service; and Chiller Chemistry and Chill Smart services. In addition, the company participates in the generation of carbon offset projects. It serves commercial, industrial, and governmental customers, as well as refrigerant wholesalers, distributors, contractors, and refrigeration equipment manufacturers. Hudson Technologies, Inc. was founded in 1991 and is headquartered in Pearl River, New York.
Latest EW
- SEC Form 4 filed by Edwards Lifesciences Corporation
- Barclays initiated coverage on Edwards Lifesciences with a new price target
- Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026
- Edwards Lifesciences to Host Investor Event in Conjunction With TCT
- Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients
- SVP, Corporate Controller Dahl Andrew M. covered exercise/tax liability with 253 shares, decreasing direct ownership by 2% to 14,615 units (SEC Form 4) to satisfy withholding tax
- CVP, JAPAC Markowitz Wayne covered exercise/tax liability with 923 shares, decreasing direct ownership by 5% to 19,371 units (SEC Form 4) to satisfy tax liability
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $54,169 worth of shares (619 units at $87.51) as part of a pre-agreed trading plan (SEC Form 4)
- CVP, TMTT, Surgical & IHFM Chopra Daveen covered exercise/tax liability with 398 shares, decreasing direct ownership by 0.90% to 43,926 units (SEC Form 4) to satisfy tax liability
- Edwards Lifesciences Comments on TAVR National Coverage Decision
Latest HDSN
- Hudson Technologies to Host Conference Call to Discuss Third Quarter 2026 Results
- Large owner Hartree Partners, Lp bought $604,446 worth of shares (118,549 units at $5.10), increasing direct ownership by 2% to 5,348,517 units (SEC Form 4)
- Large owner Hartree Partners, Lp bought $68,923 worth of shares (13,515 units at $5.10), increasing direct ownership by 0.26% to 5,229,968 units (SEC Form 4)
- Large owner Hartree Partners, Lp bought $56,794 worth of shares (11,136 units at $5.10), increasing direct ownership by 0.21% to 5,216,453 units (SEC Form 4)
- Hudson Technologies Signs Joint Development Agreement with Icorium; Expands Commitment to Commercialize and Scale Patented Extractive Distillation Technology
- Large owner Hartree Partners, Lp bought $27,117 worth of shares (5,317 units at $5.10), increasing direct ownership by 0.10% to 5,205,317 units (SEC Form 4)
- Large owner Hartree Partners, Lp bought $553,047 worth of shares (100,612 units at $5.50), increasing direct ownership by 2% to 5,200,000 units (SEC Form 4)
- Hudson Technologies to Host Climate Week NYC 2026 Panel Discussion
- Large owner Hartree Partners, Lp bought $28,589 worth of shares (5,198 units at $5.50), increasing direct ownership by 0.10% to 5,099,388 units (SEC Form 4)
- SEC Form 10-Q filed by Hudson Technologies Inc.